{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:56:25Z","timestamp":1792252585007,"version":"4.4.0"},"reference-count":315,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004541","name":"Ministry of Education, India","doi-asserted-by":"publisher","award":["STARS2\/2023-0209"],"award-info":[{"award-number":["STARS2\/2023-0209"]}],"id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.virol.2025.110394","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T19:25:48Z","timestamp":1736537148000},"page":"110394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction"],"prefix":"10.1016","volume":"604","author":[{"given":"Ankita","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanshu","family":"Walia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravindra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-003X","authenticated-orcid":false,"given":"Shailly","family":"Tomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2025.110394_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jiab361","article-title":"Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model","volume":"224","author":"Abdelnabi","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11481-020-09924-9","article-title":"SARS-CoV-2 infection leads to neurological dysfunction","volume":"15","author":"Acharya","year":"2020","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.virol.2025.110394_bib3","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2666-5247(21)00358-X","article-title":"Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults","volume":"3","author":"Ahn","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.virol.2025.110394_bib4","article-title":"Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: a randomized, observer-blind phase 1 study","volume":"4","author":"Akahata","year":"2023","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.virol.2025.110394_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/pathogens9050331","article-title":"The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms","volume":"9","author":"Alanagreh","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.virol.2025.110394_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41541-022-00528-3","article-title":"SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN\u00ae, induces robust humoral and cellular immunity in mice and non-human primates","volume":"7","author":"Alimohammadi","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virol.2025.110394_bib7","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S2213-2600(21)00458-6","article-title":"Waning immunity to SARS-CoV-2: implications for vaccine booster strategies","volume":"9","author":"Altmann","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.virol.2025.110394_bib8","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","article-title":"Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives","volume":"12","author":"Amporndanai","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Ang\u00e9lica","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib10","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s42003-023-05469-8","article-title":"Insights into the mechanism of SARS-CoV-2 main protease autocatalytic maturation from model precursors","volume":"6","author":"Aniana","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib11","article-title":"Discovery and evaluation of entry inhibitors for SARS-CoV-2 and its emerging variants","volume":"95","author":"Arpan","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110394_bib12","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1016\/j.cub.2021.01.006","article-title":"Herd immunity","volume":"31","author":"Ashby","year":"2021","journal-title":"Curr. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib14","article-title":"SARS-CoV-2 nucleocapsid protein is a potential therapeutic target for anticoronavirus drug discovery","volume":"11","author":"Austin","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.virol.2025.110394_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41587-023-02101-2","article-title":"First self-amplifying mRNA vaccine approved","volume":"42","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.virol.2025.110394_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.20411\/pai.v6i1.408","article-title":"Alpha 1 antitrypsin is an inhibitor of the SARS-CoV-2\u2013priming protease TMPRSS2","volume":"6","author":"Azouz","year":"2021","journal-title":"Pathog. Immun."},{"key":"10.1016\/j.virol.2025.110394_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib19","article-title":"Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose vaccine and as a booster against SARS-CoV-2 variants","volume":"2022","author":"Beavis","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2025.110394_bib20","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000786","article-title":"TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells","volume":"3","author":"Bestle","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.virol.2025.110394_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/vaccines9020147","article-title":"SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2025.110394_bib22","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa2004500","article-title":"Covid-19 in critically ill patients in the Seattle region \u2014 case series","volume":"382","author":"Bhatraju","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2022.959586","article-title":"Virus-host protein-protein interactions as molecular drug targets for arboviral infections","volume":"2","author":"Bhutkar","year":"2022","journal-title":"Front. Virol."},{"key":"10.1016\/j.virol.2025.110394_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110111","article-title":"Viral methyltransferase inhibitors: berbamine, venetoclax, and ponatinib as efficacious antivirals against chikungunya virus","volume":"759","author":"Bhutkar","year":"2024","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.virol.2025.110394_bib25","series-title":"ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001 - ACM Biolabs","author":"Biolabs","year":"2024"},{"key":"10.1016\/j.virol.2025.110394_bib26","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1128\/JVI.77.4.2530-2538.2003","article-title":"Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E","volume":"77","author":"Bonavia","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110394_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2023.199221","article-title":"Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function","volume":"336","author":"Boniardi","year":"2023","journal-title":"Virus Res."},{"key":"10.1016\/j.virol.2025.110394_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2017.02374","article-title":"Causes and consequences of flavivirus RNA methylation","volume":"8","author":"Bradrick","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virol.2025.110394_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(22)00055-1","article-title":"Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial","volume":"399","author":"Bravo","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2025.110394_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02916-22","article-title":"Why molnupiravir fails in hospitalized patients","volume":"13","author":"Brown","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.virol.2025.110394_bib30","article-title":"COVID-19 disease incidence and severity in persons previously infected and unvaccinated vs previously uninfected and vaccinated","volume":"484","author":"Butt","year":"2024","journal-title":"J. Infect. Dis. jiae"},{"key":"10.1016\/j.virol.2025.110394_bib31","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","article-title":"Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities","volume":"65","author":"Cannalire","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2025.110394_bib32","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2025.110394_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/v14020353","article-title":"Screening of botanical drugs against SARS-CoV-2 entry reveals novel therapeutic agents to treat COVID-19","volume":"14","author":"Cao","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2025.110394_bib34","article-title":"GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial","volume":"4","author":"Capone","year":"2023","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.virol.2025.110394_bib35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41541-021-00414-4","article-title":"SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses","volume":"6","author":"Carmen","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virol.2025.110394_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1268854","article-title":"Lipid compartments and lipid metabolism as therapeutic targets against coronavirus","volume":"14","author":"Cesar-Silva","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.virol.2025.110394_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1039\/C5MB00582E","article-title":"Structure-based virtual screening and experimental validation of the discovery of inhibitors targeted towards the human coronavirus nucleocapsid protein","volume":"12","author":"Chang","year":"2015","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.virol.2025.110394_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12250-016-3726-4","article-title":"Molecular mechanisms of coronavirus RNA capping and methylation","volume":"31","author":"Chen","year":"2016","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virol.2025.110394_bib40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s13238-014-0026-3","article-title":"SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex","volume":"5","author":"Chen","year":"2014","journal-title":"Protein Cell"},{"key":"10.1016\/j.virol.2025.110394_bib41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jinf.2020.12.005","article-title":"Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients","volume":"82","author":"Chen","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.virol.2025.110394_bib42","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1016\/j.vaccine.2022.07.033","volume":"40","author":"Chen","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2025.110394_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108254","article-title":"Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects","volume":"33","author":"Cheng","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.virol.2025.110394_bib44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12985-021-01624-x","article-title":"Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics","volume":"18","author":"Chitsike","year":"2021","journal-title":"Virol. J."},{"key":"10.1016\/j.virol.2025.110394_bib45","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2666-5247(22)00027-1","article-title":"Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial","volume":"3","author":"Chiuppesi","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.virol.2025.110394_bib46","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3389\/fimmu.2020.01664","article-title":"Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach","volume":"11","author":"Choudhary","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/iub.2793","article-title":"Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease","volume":"76","author":"Choudhary","year":"2023","journal-title":"IUBMB Life"},{"key":"10.1016\/j.virol.2025.110394_bib48","article-title":"Activity profiling of deubiquitinating inhibitors-bound to SARS-CoV-2 papain like protease with antiviral efficacy in murine infection model therapies","author":"Choudhary","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2025.110394_bib49","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2025.110394_bib50","series-title":"U.S. National Library of Medicine","year":"2024"},{"key":"10.1016\/j.virol.2025.110394_bib51","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10072-021-05741-x","article-title":"Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech\/Pfizer) COVID-19 vaccine\u2014a case report","volume":"43","author":"Consoli","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.virol.2025.110394_bib52","series-title":"Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid","author":"Cox","year":"2024"},{"key":"10.1016\/j.virol.2025.110394_bib53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virol.2025.110394_bib54","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.str.2024.08.005","article-title":"Structural review of SARS-CoV-2 antiviral targets","volume":"32","author":"Cui","year":"2024","journal-title":"Structure"},{"key":"10.1016\/j.virol.2025.110394_bib56","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2025.110394_bib57","first-page":"e00909","article-title":"Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries","volume":"68","author":"Dario","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2025.110394_bib58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virol.2025.110394_bib59","doi-asserted-by":"crossref","DOI":"10.5812\/archcid.13823","article-title":"Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study","volume":"12","author":"Dayer","year":"2017","journal-title":"Arch. Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib60","series-title":"Antiviral Strategies","first-page":"53","article-title":"Antiviral agents acting as DNA or RNA chain terminators","author":"De Clercq","year":"2009"},{"key":"10.1016\/j.virol.2025.110394_bib61","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.tins.2020.04.004","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the central nervous system","volume":"43","author":"De Felice","year":"2020","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.virol.2025.110394_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01819-20","article-title":"A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19","volume":"95","author":"De Vries","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2025.110394_bib63","first-page":"6771","volume":"vol. 117","author":"de Wit","year":"2020"},{"key":"10.1016\/j.virol.2025.110394_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109820","article-title":"Mechanistic and thermodynamic characterization of antiviral inhibitors targeting nucleocapsid N-terminal domain of SARS-CoV-2","volume":"750","author":"Dhaka","year":"2023","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.virol.2025.110394_bib66","article-title":"Structural insights into the RNA binding inhibitors of the C-terminal domain of the SARS-CoV-2 nucleocapsid","author":"Dhaka","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2025.110394_bib67","article-title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics","volume":"1\u20137","author":"Dhama","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2025.110394_bib68","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1080\/07391102.2020.1852968","article-title":"Computational guided identification of novel potent inhibitors of N-terminal domain of nucleocapsid protein of severe acute respiratory syndrome coronavirus 2","volume":"40","author":"Dhankhar","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.virol.2025.110394_bib69","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.4103\/2468-8827.330656","article-title":"Enveloped virus-like particles as a platform for vaccine development","volume":"6","author":"Diaz-Mitoma","year":"2021","journal-title":"Int. J. Noncommun. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib70","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1016\/j.vaccine.2024.04.084","article-title":"A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: a phase 3, randomised, placebo-controlled clinical trial","volume":"42","author":"Dinh Thiem","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2025.110394_bib71","article-title":"The substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir","volume":"14","author":"Dirk","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.virol.2025.110394_bib72","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1099\/vir.0.062208-0","article-title":"Flavivirus RNA methylation","volume":"95","author":"Dong","year":"2014","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2025.110394_bib73","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1038\/s41467-020-18709-w","article-title":"Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease","volume":"11","author":"Douangamath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib74","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.virol.2025.110394_bib75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00284-021-02724-1","article-title":"Emerging SARS-CoV-2 variants: genetic variability and clinical implications","volume":"79","author":"Dubey","year":"2021","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.virol.2025.110394_bib76","doi-asserted-by":"crossref","DOI":"10.3201\/eid3002.230768","article-title":"Key challenges for respiratory virus surveillance while transitioning out of acute phase of COVID-19 pandemic","volume":"30","author":"Eales","year":"2024","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib77","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib78","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102372","article-title":"Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)","volume":"67","author":"Fang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib80","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1038\/s41467-022-31097-7","article-title":"A global lipid map reveals host dependency factors conserved across SARS-CoV-2 variants","volume":"13","author":"Farley","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib81","series-title":"Janssen COVID-19 Vaccine","year":"2024"},{"key":"10.1016\/j.virol.2025.110394_bib82","series-title":"Novavax COVID-19 Vaccine, Adjuvanted","year":"2024"},{"key":"10.1016\/j.virol.2025.110394_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00825-20","article-title":"Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production","volume":"64","author":"Fintelman-Rodrigues","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2025.110394_bib84","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/futurepharmacol3010006","article-title":"SARS-CoV-2 Mpro inhibitors: achieved diversity, developing resistance and future strategies","volume":"3","author":"Fischer","year":"2023","journal-title":"Fut. Pharmacol."},{"key":"10.1016\/j.virol.2025.110394_bib85","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib86","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1021\/acs.jpclett.0c03119","article-title":"Kobophenol A inhibits binding of host ACE2 receptor with spike RBD domain of SARS-CoV-2, a lead compound for blocking COVID-19","volume":"12","author":"Gangadevi","year":"2021","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.virol.2025.110394_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154942","article-title":"Kaempferol inhibits SARS-CoV-2 invasion by impairing heptad repeats-mediated viral fusion","volume":"118","author":"Gao","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.virol.2025.110394_bib88","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1038\/s41467-021-23469-2","article-title":"Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection","volume":"12","author":"Gharbharan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib89","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02479-20","article-title":"AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19","volume":"65","author":"Good","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2025.110394_bib90","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3390\/v15091828","article-title":"Safety and immunogenicity of inactivated whole virion COVID-19 vaccine CoviVac in clinical trials in 18\u201360 and 60+ age cohorts","volume":"15","author":"Gordeychuk","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2025.110394_bib91","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMp2305081","article-title":"The origins of covid-19 \u2014 why it matters (and why it doesn't)","volume":"388","author":"Gostin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib92","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.scib.2020.12.005","article-title":"Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2","volume":"66","author":"Gu","year":"2021","journal-title":"Sci. Bull."},{"key":"10.1016\/j.virol.2025.110394_bib93","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.ijid.2023.04.027","article-title":"Cuban vaccines Abdala and mambisa against COVID-19","volume":"130","author":"Guillen","year":"2023","journal-title":"Int. J. Infect. Dis."},{"issue":"372","key":"10.1016\/j.virol.2025.110394_bib94","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.abf7945","article-title":"X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease","author":"G\u00fcnther","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.virol.2025.110394_bib95","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.medj.2024.06.013","article-title":"Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"5","author":"Hannawi","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.virol.2025.110394_bib96","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virol.2025.110394_bib97","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A single-dose intranasal Chad vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2025.110394_bib98","doi-asserted-by":"crossref","first-page":"12600","DOI":"10.1039\/D1SC01494C","article-title":"Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties","volume":"12","author":"Hempel","year":"2021","journal-title":"Chem. Sci."},{"key":"10.1016\/j.virol.2025.110394_bib99","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.virol.2025.110394_bib100","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-024-47905-1","article-title":"Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials","volume":"15","author":"H\u1ed3","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib101","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2025.110394_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor article SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2025.110394_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103255","article-title":"Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity","volume":"65","author":"Hoffmann","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib104","doi-asserted-by":"crossref","first-page":"eabg7156","DOI":"10.1126\/sciadv.abg7156","article-title":"Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates","volume":"7","author":"Hong","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.virol.2025.110394_bib105","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2217\/fvl-2023-0115","article-title":"Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)","volume":"18","author":"Horga","year":"2023","journal-title":"Future Virol."},{"key":"10.1016\/j.virol.2025.110394_bib106","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virol.2025.110394_bib107","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.virol.2025.110394_bib108","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2025.110394_bib109","article-title":"Antiviral activity of type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2","volume":"11","author":"Idoia","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.virol.2025.110394_bib110","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.virol.2025.110394_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe5511","article-title":"Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients","volume":"5","author":"Isho","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib112","doi-asserted-by":"crossref","first-page":"15748","DOI":"10.1073\/pnas.0403812101","article-title":"CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus","volume":"101","author":"Jeffers","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2025.110394_bib113","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Jennifer","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib114","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26.COV2.S","volume":"386","author":"Jerald","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2025.110394_bib116","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","article-title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur","volume":"27","author":"Jin","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105492","article-title":"Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model","volume":"209","author":"Johnson","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2025.110394_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1122389","article-title":"Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result","volume":"14","author":"Jonny","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib119","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41392-022-01295-2","article-title":"Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial","volume":"8","author":"Kaabi","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2025.110394_bib120","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib121","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41541-021-00324-5","article-title":"Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models","volume":"6","author":"Kalnin","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virol.2025.110394_bib122","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1002\/iid3.604","article-title":"Oral and intranasal vaccines against SARS-CoV-2: current progress, prospects, advantages, and challenges","volume":"10","author":"Kar","year":"2022","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101526","article-title":"Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in\u00ae, in healthy adults: a multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up","volume":"50","author":"Khairullin","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib124","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2025.110394_bib126","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cell.2020.04.011","article-title":"The architecture of SARS-CoV-2 transcriptome","volume":"181","author":"Kim","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2025.110394_bib127","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1016\/j.vaccine.2023.06.013","article-title":"Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost","volume":"41","author":"Kim","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2025.110394_bib128","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/s41467-019-10280-3","article-title":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors","volume":"10","author":"Kirchdoerfer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib129","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain\u2010like protease, PLpro, of SARS\u2010CoV\u20102","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.virol.2025.110394_bib130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","author":"Kokic","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib131","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3390\/vaccines11121767","article-title":"A phase I\/II clinical trial of intradermal, controllable self-replicating ribonucleic acid vaccine EXG-5003 against SARS-CoV-2","volume":"11","author":"Koseki","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2025.110394_bib132","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41467-020-17495-9","article-title":"Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin","volume":"11","author":"Krafcikova","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib133","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2025.110394_bib134","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib135","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/vaccines11020326","article-title":"Safety and immunogenicity of betuvax-CoV-2, an RBD-fc-based SARS-CoV-2 recombinant vaccine: preliminary results of the first-in-human, randomized, double-blind, placebo-controlled phase I\/II clinical trial","volume":"11","author":"Kudriavtsev","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2025.110394_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2021.107969","article-title":"Multifunctional inhibitors of SARS-CoV-2 by MM\/PBSA, essential dynamics, and molecular dynamic investigations","volume":"107","author":"Kumar","year":"2021","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.virol.2025.110394_bib137","article-title":"The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19","volume":"12","author":"Kun","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.virol.2025.110394_bib138","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virol.2025.110394_bib139","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir: first approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.virol.2025.110394_bib140","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/S1473-3099(22)00502-3","article-title":"Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial","volume":"22","author":"Lazarus","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib141","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1038\/s41467-020-19662-4","article-title":"Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib142","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46233-6","article-title":"Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models","volume":"13","author":"Lelis","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2025.110394_bib143","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(21)02841-5","article-title":"Managing waning vaccine protection against SARS-CoV-2 variants","volume":"399","author":"Leung","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2025.110394_bib144","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41392-021-00592-6","article-title":"SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2025.110394_bib145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-021-01677-z","article-title":"Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial","volume":"28","author":"Li","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2025.110394_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105606","article-title":"Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2","volume":"214","author":"Li","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2025.110394_bib147","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","article-title":"Efficacy and safety of the RBD-dimer\u2013based covid-19 vaccine ZF2001 in adults","volume":"386","author":"Lianpan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib148","doi-asserted-by":"crossref","first-page":"315","DOI":"10.7774\/cevr.2024.13.4.315","article-title":"Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial","volume":"13","author":"Lim","year":"2024","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.virol.2025.110394_bib149","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/jm500089r","article-title":"Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target","volume":"57","author":"Lin","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2025.110394_bib150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","article-title":"Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes","volume":"150","author":"Lin","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2025.110394_bib151","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41418-021-00909-6","article-title":"SARS-CoV-2 therapeutic targets: RNA proofreading complex and virus-induced senescence","volume":"29","author":"Lin","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.virol.2025.110394_bib152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278878","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia","volume":"18","author":"Lioznov","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2025.110394_bib153","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","article-title":"SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact","volume":"22","author":"Lipsitch","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib154","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41422-022-00681-3","article-title":"Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults","volume":"32","author":"Liu","year":"2022","journal-title":"Cell Res."},{"key":"10.1016\/j.virol.2025.110394_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102231","article-title":"Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial","volume":"64","author":"Liu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib156","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2025.110394_bib157","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29927","article-title":"Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines","volume":"96","author":"Lovell","year":"2024","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virol.2025.110394_bib158","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41541-022-00590-x","article-title":"A phase I\/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine","volume":"7","author":"Low","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virol.2025.110394_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105389","article-title":"Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro","volume":"206","author":"Lu","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2025.110394_bib160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12879-023-08835-3","article-title":"Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial","volume":"24","author":"Luvira","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib161","doi-asserted-by":"crossref","first-page":"veae020","DOI":"10.1093\/ve\/veae020","article-title":"Evolutionary trajectory of diverse SARS-CoV-2 variants at the beginning of COVID-19 outbreak","volume":"10","author":"Lv","year":"2024","journal-title":"Virus Evol."},{"key":"10.1016\/j.virol.2025.110394_bib162","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.virol.2025.110394_bib163","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","article-title":"Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay","volume":"7","author":"Ma","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.virol.2025.110394_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116356","article-title":"Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens","volume":"46","author":"Mahajan","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.virol.2025.110394_bib165","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2108728118","article-title":"A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells","volume":"118","author":"Mahoney","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2025.110394_bib166","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41594-020-00536-8","article-title":"Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers","volume":"27","author":"Mandala","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib167","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.medj.2023.12.004","article-title":"Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19","volume":"5","author":"Mao","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.virol.2025.110394_bib168","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.ymthe.2022.01.001","article-title":"A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models","volume":"30","author":"Maruggi","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2025.110394_bib169","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/biology10060454","article-title":"Viewing SARS-CoV-2 nucleocapsid protein in terms of molecular flexibility","volume":"10","author":"Matsuo","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.virol.2025.110394_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02220-20","article-title":"From people to Panthera: natural SARS-CoV-2 infection in tigers and lions at the bronx zoo","volume":"11","author":"McAloose","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.virol.2025.110394_bib170","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41392-020-00335-z","article-title":"SARS-CoV-2: the many pros of targeting PLpro","volume":"5","author":"McClain","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2025.110394_bib171","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.671263","article-title":"Current strategies of antiviral drug discovery for COVID-19","volume":"8","author":"Mei","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.virol.2025.110394_bib172","article-title":"Target discovery for host-directed antiviral therapies: application of proteomics approaches","volume":"6","author":"Merve","year":"2021","journal-title":"mSystems"},{"key":"10.1016\/j.virol.2025.110394_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102374","article-title":"Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study","volume":"67","author":"Mi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33040","article-title":"The reverse zoonotic potential of SARS-CoV-2","volume":"10","author":"Milich","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.virol.2025.110394_bib175","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac177","article-title":"Effectiveness of coronavirus disease 2019 vaccines in preventing infection, hospital admission, and death: a historical cohort study using Iranian registration data during vaccination program","volume":"9","author":"Mirahmadizadeh","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib176","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4269\/ajtmh.20-0849","article-title":"The origin of COVID-19 and why it matters","volume":"103","author":"Morens","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.virol.2025.110394_bib177","unstructured":"mRNA COVID-19 vaccine, 2024.FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants | FDA. https:\/\/doi.org\/www.fda.gov\/news-events\/press-announcements\/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently."},{"issue":"4","key":"10.1016\/j.virol.2025.110394_bib178","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/1873-3468.13642","article-title":"Inhibition of Chikungunya virus by an adenosine analog targeting the SAM-dependent nsP1 methyltransferase","volume":"594","author":"Mudgal","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.virol.2025.110394_bib179","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1080\/21645515.2020.1805992","article-title":"Prospects for mucosal vaccine: shutting the door on SARS-CoV-2","volume":"16","author":"Mudgal","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2025.110394_bib180","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01943-21","article-title":"Selective estrogen receptor modulators limit alphavirus infection by targeting the viral capping enzyme nsP1","volume":"66","author":"Mudgal","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2025.110394_bib181","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1080\/07391102.2022.2045221","article-title":"In silico and in vitro evaluation of imatinib as an inhibitor for SARS-CoV-2","volume":"41","author":"Mulgaonkar","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.virol.2025.110394_bib182","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3390\/vaccines11101535","article-title":"Long term follow-up study of a randomized, open-label, uncontrolled, phase I\/II study to assess the safety and immunogenicity of intramuscular and intradermal doses of COVID-19 DNA vaccine (AG0302-COVID19)","volume":"11","author":"Nakagami","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2025.110394_bib183","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.chembiol.2021.11.006","article-title":"Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses","volume":"29","author":"Napolitano","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib184","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s42003-022-03090-9","article-title":"Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay","volume":"5","author":"Narayanan","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib186","article-title":"Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: interim results of a double-blind, randomised controlled phase 1 and 2 trial","volume":"24","author":"Nguyen","year":"2022","journal-title":"Lancet Reg. Health West Pac."},{"key":"10.1016\/j.virol.2025.110394_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104878","article-title":"Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster","volume":"98","author":"Nolan","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib188","doi-asserted-by":"crossref","first-page":"159.03","DOI":"10.4049\/jimmunol.210.Supp.159.03","article-title":"Antigen presenting cell targeted T cell DNA vaccine inducing strong and specific cellular responses across multiple T cell epitopes of SARS-COV-2","volume":"210","author":"Norheim","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103004","article-title":"Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease","volume":"299","author":"Noske","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2025.110394_bib190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271112","article-title":"Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2","volume":"17","author":"Ohishi","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2025.110394_bib191","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1012416","article-title":"Surveillance strategies for the detection of new pathogen variants across epidemiological contexts","volume":"20","author":"Oliveira Roster","year":"2024","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib192","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.23.2001005","article-title":"SARS-CoV-2 infection in farmed minks, The Netherlands, April and May 2020","volume":"25","author":"Oreshkova","year":"2020","journal-title":"Euro Surveill."},{"key":"10.1016\/j.virol.2025.110394_bib193","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.virol.2025.110394_bib194","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1038\/s41467-023-39053-9","article-title":"GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for \u22656 months in previously-vaccinated older adults","volume":"14","author":"Palmer","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004659","article-title":"Viral and cellular proteins containing FGDF motifs bind G3BP to block stress granule formation","volume":"11","author":"Panas","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2025.110394_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115491","article-title":"The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022","volume":"257","author":"Pang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.virol.2025.110394_bib197","article-title":"Editorial: current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients","volume":"28","author":"Parums","year":"2022","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.virol.2025.110394_bib198","article-title":"SARS-CoV-2 nucleocapsid protein phase-separates with RNA and with human hnRNPs","volume":"39","author":"Peng","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.virol.2025.110394_bib199","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106478","article-title":"SARS\u2010CoV\u20102 nucleocapsid protein phase\u2010separates with RNA and with human hnRNPs","volume":"39","author":"Perdikari","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.virol.2025.110394_bib200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000511","article-title":"Structure and inhibition of the SARS coronavirus envelope protein ion channel","volume":"5","author":"Pervushin","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2025.110394_bib201","article-title":"Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance","author":"Phan","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2025.110394_bib202","series-title":"HDT Bio","author":"Pipeline","year":"2024"},{"key":"10.1016\/j.virol.2025.110394_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101323","article-title":"Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomised, placebo-controlled, phase 1 trial","volume":"45","author":"Pitisuttithum","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib204","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib205","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00562-24","article-title":"Design of novel and highly selective SARS-CoV-2 main protease inhibitors","volume":"68","author":"Poli","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2025.110394_bib206","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1021\/cr010182v","article-title":"Irreversible inhibitors of serine, cysteine, and threonine proteases","volume":"102","author":"Powers","year":"2002","journal-title":"Chem. Rev."},{"key":"10.1016\/j.virol.2025.110394_bib207","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/s41598-023-49653-6","article-title":"Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study","volume":"14","author":"Puthanakit","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2025.110394_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106288","article-title":"N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial","volume":"89","author":"Rabdano","year":"2024","journal-title":"J. Infect."},{"key":"10.1016\/j.virol.2025.110394_bib209","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1093\/nar\/gkw551","article-title":"mRNA capping: biological functions and applications","volume":"44","author":"Ramanathan","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virol.2025.110394_bib210","doi-asserted-by":"crossref","first-page":"e863","DOI":"10.1016\/S2666-5247(23)00177-5","volume":"4","author":"Ramasamy","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.virol.2025.110394_bib211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2022.08.008","article-title":"Multi-target direct-acting SARS-CoV-2 antivirals against the nucleotide-binding pockets of virus-specific proteins","volume":"577","author":"Rani","year":"2022","journal-title":"Virology"},{"key":"10.1016\/j.virol.2025.110394_bib125","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2025.110394_bib212","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1038\/s41598-024-55320-1","article-title":"Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study","volume":"14","author":"Reiter","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2025.110394_bib213","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.910136","article-title":"Heterologous saRNA prime, DNA dual-antigen boost SARS-CoV-2 vaccination elicits robust cellular immunogenicity and cross-variant neutralizing antibodies","volume":"13","author":"Rice","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104138","article-title":"Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial","volume":"82","author":"Robbins","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.lansea.2023.100141","article-title":"Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 and BBV152: a non-inferiority phase 4, participant and observer-blinded, randomised study","volume":"12","author":"Rose","year":"2023","journal-title":"The Lancet Regional Health - Southeast Asia"},{"key":"10.1016\/j.virol.2025.110394_bib216","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/vaccines11020318","article-title":"Assessment of immunogenicity and efficacy of CV0501 mRNA-based Omicron COVID-19 vaccination in small animal models","volume":"11","author":"Roth","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2025.110394_bib217","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12985-024-02299-w","article-title":"Quercetin inhibits SARS-CoV-2 infection and prevents syncytium formation by cells co-expressing the viral spike protein and human ACE2","volume":"21","author":"Roy","year":"2024","journal-title":"Virol. J."},{"key":"10.1016\/j.virol.2025.110394_bib218","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/vaccines11050998","article-title":"Assessment of safety and prophylactic efficacy of the EpiVacCorona peptide vaccine for COVID-19 prevention (phase III)","volume":"11","author":"Ryzhikov","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2025.110394_bib219","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkab072","article-title":"In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19","volume":"76","author":"Sacramento","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virol.2025.110394_bib220","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1093\/jac\/dkaa334","article-title":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","volume":"75","author":"Sadeghi","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virol.2025.110394_bib221","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41591-024-02955-2","article-title":"An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2\/3 randomized trial","volume":"30","author":"Saraf","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2025.110394_bib222","doi-asserted-by":"crossref","first-page":"9904","DOI":"10.1039\/D0SC02646H","article-title":"Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors","volume":"11","author":"Sargsyan","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.virol.2025.110394_bib223","doi-asserted-by":"crossref","first-page":"12048","DOI":"10.1080\/07391102.2021.1969285","article-title":"MD simulation and MM\/PBSA identifies phytochemicals as bifunctional inhibitors of SARS-CoV-2","volume":"40","author":"Sharma","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.virol.2025.110394_bib224","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.virol.2025.110394_bib225","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity","volume":"65","author":"Shen","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2025.110394_bib226","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2025.110394_bib227","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3390\/vaccines11121771","article-title":"Pre-clinical safety and immunogenicity study of a coronavirus protein-based subunit vaccine for COVID-19","volume":"11","author":"Shorayeva","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2025.110394_bib228","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa2031304","article-title":"A randomized trial of convalescent plasma in covid-19 severe pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib229","article-title":"Antiviral agents for the treatment of COVID-19: progress and challenges","volume":"3","author":"Singh","year":"2022","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.virol.2025.110394_bib230","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biochi.2018.04.004","article-title":"Chikungunya virus inhibition by peptidomimetic inhibitors targeting virus-specific cysteine protease","volume":"149","author":"Singh","year":"2018","journal-title":"Biochimie"},{"key":"10.1016\/j.virol.2025.110394_bib231","article-title":"Chimeric chikungunya virus-like particles with surface exposed SARS-CoV-2 RBD elicits potent immunogenic responses in mice","author":"Singh","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2025.110394_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150746","article-title":"Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody","volume":"734","author":"Singh","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib233","article-title":"Designing and bioengineering of CDRs with higher affinity against receptor-binding domain (RBD) of SARS-CoV-2 Omicron variant","author":"Singh","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.virol.2025.110394_bib234","article-title":"Structural and mechanistic insights into Main protease (Mpro) dimer interface destabilization inhibitor: unveiling new therapeutic avenues against SARS-CoV-2","author":"Singh","year":"2024","journal-title":"Chemrxiv"},{"key":"10.1016\/j.virol.2025.110394_bib235","author":"Singh"},{"key":"10.1016\/j.virol.2025.110394_bib236","series-title":"The Sinopharm COVID-19 Vaccine: what You Need to Know","year":"2022"},{"key":"10.1016\/j.virol.2025.110394_bib237","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/S2666-5247(22)00337-8","article-title":"First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2","volume":"4","author":"Smit","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.virol.2025.110394_bib238","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1016\/j.vaccine.2023.05.016","article-title":"Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials","volume":"41","author":"Smith","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2025.110394_bib239","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12985-023-02121-z","article-title":"Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial","volume":"20","author":"Solaymani-Dodaran","year":"2023","journal-title":"Virol. J."},{"key":"10.1016\/j.virol.2025.110394_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102140","article-title":"Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial","volume":"64","author":"Song","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib241","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115572","article-title":"Design, synthesis, antiviral evaluation, and in silico studies of acrylamides targeting nsP2 from Chikungunya virus","volume":"258","author":"Souza","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.virol.2025.110394_bib242","unstructured":"SPIKEVAX | FDA. https:\/\/doi.org\/www.fda.gov\/vaccines-blood-biologics\/spikevax."},{"key":"10.1016\/j.virol.2025.110394_bib243","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3390\/v14112367","article-title":"Infection with SARS-CoV-2 variants is associated with different long COVID phenotypes","volume":"14","author":"Spinicci","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2025.110394_bib244","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s42003-022-03737-7","article-title":"Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease","volume":"5","author":"Srinivasan","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib245","article-title":"Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.virol.2025.110394_bib246","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cytogfr.2020.04.002","article-title":"Cytokine storm intervention in the early stages of COVID-19 pneumonia","volume":"53","author":"Sun","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.virol.2025.110394_bib247","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3390\/vaccines10071014","article-title":"Safety and immunogenicity of inactivated Bacillus subtilis spores as a heterologous antibody booster for COVID-19 vaccines","volume":"10","author":"Sung","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2025.110394_bib248","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1445459","article-title":"Booster vaccination using bivalent DS-5670a\/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5\u201311 years: a phase 2\/3, randomized, active-controlled study","volume":"15","author":"Suzuki","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib249","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103213","article-title":"6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro","volume":"24","author":"Swaim","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.virol.2025.110394_bib250","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101823","article-title":"COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2","volume":"56","author":"Szubert","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib251","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imm.13540","article-title":"Immunogenicity and safety of SpikoGen\u00ae, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: a randomized placebo-controlled trial","volume":"167","author":"Tabarsi","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.virol.2025.110394_bib252","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12917-024-03892-5","article-title":"Seroevidence of SARS-CoV-2 spillback to rodents in sarawak, Malaysian borneo","volume":"20","author":"Tan","year":"2024","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.virol.2025.110394_bib253","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1126\/science.adm9724","article-title":"Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model","volume":"383","author":"Tan","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.virol.2025.110394_bib254","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/vaccines12020175","article-title":"Immunogenicity of tetravalent protein vaccine sctv01e-2 against SARS-CoV-2 EG.5 subvaraint: a phase 2 trial","volume":"12","author":"Tang","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2025.110394_bib255","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3390\/vaccines10111865","article-title":"Efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac in healthy subjects: a randomized, observer-blinded, non-inferiority phase III trial","volume":"10","author":"Tanriover","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.virol.2025.110394_bib256","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/v14010008","article-title":"Activity of Galidesivir in a hamster model of SARS-CoV-2","volume":"14","author":"Taylor","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2025.110394_bib257","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib258","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100129","article-title":"The roles of lipids in SARS-CoV-2 viral replication and the host immune response","volume":"62","author":"Theken","year":"2021","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.virol.2025.110394_bib259","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.855496","article-title":"Molnupiravir and its antiviral activity against COVID-19","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib260","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41541-022-00509-6","article-title":"Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2","volume":"7","author":"Tioni","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virol.2025.110394_bib261","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2022.100423","article-title":"Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial","volume":"18","author":"Toledo-Roman\u00ed","year":"2023","journal-title":"The Lancet Regional Health - Americas"},{"key":"10.1016\/j.virol.2025.110394_bib262","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.vaccine.2022.10.030","article-title":"An evaluation of the safety and immunogenicity of MVC-COV1901: results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay","volume":"41","author":"Torales","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2025.110394_bib263","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib264","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.3390\/v15112254","article-title":"Screening drugs for broad-spectrum, host-directed antiviral activity: lessons from the development of probenecid for COVID-19","volume":"15","author":"Tripp","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2025.110394_bib265","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","author":"van Riel","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.virol.2025.110394_bib266","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103811","article-title":"Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1\/2 randomised, double-blind, placebo-controlled, dose-ranging trial","volume":"75","author":"Vanhoutte","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.virol.2025.110394_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105998","article-title":"Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein","volume":"56","author":"Vankadari","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.virol.2025.110394_bib268","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.virol.2025.110394_bib269","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.virol.2025.110394_bib270","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.virol.2025.110394_bib271","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.virol.2025.110394_bib272","first-page":"4538","article-title":"Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.virol.2025.110394_bib273","volume":"vol. 118","author":"Wang","year":"2021"},{"key":"10.1016\/j.virol.2025.110394_bib274","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1021\/acsnano.0c06836","article-title":"Membrane nanoparticles derived from ACE2-rich cells block SARS-CoV-2 infection","volume":"15","author":"Wang","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.virol.2025.110394_bib275","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.virol.2025.110394_bib276","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157707","article-title":"A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants","volume":"132","author":"Wang","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2025.110394_bib277","article-title":"Efficacy of heterologous boosting using recombinant SARS-CoV-2 fusion protein vaccine: a randomized, double-blind and placebo-controlled phase III trial","author":"Wang","year":"2022","journal-title":"SSRN Electron. J."},{"key":"10.1016\/j.virol.2025.110394_bib278","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2025.110394_bib279","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.virol.2025.110394_bib280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/em.22471","article-title":"Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir","volume":"63","author":"Waters","year":"2022","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.virol.2025.110394_bib281","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.apsb.2024.03.009","article-title":"Ciclopirox inhibits SARS-CoV-2 replication by promoting the degradation of the nucleocapsid protein","volume":"14","author":"Wei","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.virol.2025.110394_bib282","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Wei-jie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib283","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.virol.2025.110394_bib284","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.tim.2012.02.001","article-title":"Regulation of stress granules in virus systems","volume":"20","author":"White","year":"2012","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.virol.2025.110394_bib285","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 \u2014 interim WHO solidarity trial results","volume":"384","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110394_bib286","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virol.2025.110394_bib287","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5694\/mja2.51394","article-title":"COVID-19 mRNA vaccine (Comirnaty)-induced myocarditis","volume":"216","author":"Wong","year":"2022","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.virol.2025.110394_bib288","author":"Wood"},{"key":"10.1016\/j.virol.2025.110394_bib289","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/s41467-023-38031-5","article-title":"Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin","volume":"14","author":"Wydorski","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110394_bib290","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40121-023-00896-w","article-title":"Safety and immunogenicity of a recombinant two-component SARS-CoV-2 protein vaccine: randomized, double-blind, placebo-controlled phase I and phase II studies","volume":"13","author":"Wynne","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.virol.2025.110394_bib291","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.virol.2025.110394_bib292","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28","author":"Xie","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2025.110394_bib293","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","article-title":"Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2","volume":"11","author":"Xiong","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.virol.2025.110394_bib294","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41392-023-01691-2","article-title":"UniBind: a novel artificial intelligence-based prediction model for SARS-CoV-2 infectivity and variant evolution","volume":"8","author":"Yan","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2025.110394_bib295","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41392-020-00325-1","article-title":"Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2025.110394_bib296","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113965","article-title":"Interaction between host G3BP and viral nucleocapsid protein regulates SARS-CoV-2 replication and pathogenicity","volume":"43","author":"Yang","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.virol.2025.110394_bib297","article-title":"Inhibition of SARS-CoV-2 replication by a ssDNA aptamer targeting the nucleocapsid protein","volume":"12","author":"Yanping","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.virol.2025.110394_bib298","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S0140-6736(22)00326-9","article-title":"Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study","volume":"399","author":"Yen","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2025.110394_bib299","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2267869","article-title":"Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine","volume":"19","author":"Yong","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2025.110394_bib300","article-title":"SARS-CoV-2 Nsp5 demonstrates two distinct mechanisms targeting RIG-I and MAVS to evade the innate immune response","volume":"12","author":"Yongzhen","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.virol.2025.110394_bib301","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153364","article-title":"Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2","volume":"85","author":"Yu","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.virol.2025.110394_bib302","article-title":"Glycopeptide antibiotic teicoplanin inhibits cell entry of SARS-CoV-2 by suppressing the proteolytic activity of cathepsin L","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virol.2025.110394_bib303","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.3390\/ani10122377","article-title":"Pathology of coronavirus infections: a review of lesions in animals in the one-health perspective","volume":"10","author":"Zappulli","year":"2020","journal-title":"Animals"},{"key":"10.1016\/j.virol.2025.110394_bib304","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/CM9.0000000000000790","volume":"133","author":"Zeng","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.virol.2025.110394_bib305","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nsmb999","article-title":"Insights into SARS-CoV transcription and replication from the structure of the nsp7\u2013nsp8 hexadecamer","volume":"12","author":"Zhai","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.virol.2025.110394_bib306","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virol.2025.110394_bib307","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virol.2025.110394_bib308","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00836-9","article-title":"High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors","volume":"12","author":"Zhao","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.virol.2025.110394_bib309","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13238-021-00883-2","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332","volume":"13","author":"Zhao","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.virol.2025.110394_bib310","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41541-022-00597-4","article-title":"Challenges and developments in universal vaccine design against SARS-CoV-2 variants","volume":"7","author":"Zhao","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.virol.2025.110394_bib311","article-title":"Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2","volume":"119","author":"Zhao","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2025.110394_bib312","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome\/lysosome and block the entry of ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)","volume":"291","author":"Zhou","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2025.110394_bib313","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2025.110394_bib314","doi-asserted-by":"crossref","first-page":"eadd7197","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.virol.2025.110394_bib315","article-title":"Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2025.110394_bib316","doi-asserted-by":"crossref","first-page":"9161","DOI":"10.1038\/s41598-023-35907-w","article-title":"Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase","volume":"13","author":"Zmudzinski","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2025.110394_bib317","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/cid\/ciad494","article-title":"Nirmatrelvir resistance\u2014de Novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure\u2014a case report","volume":"78","author":"Zuckerman","year":"2024","journal-title":"Clin. Infect. Dis."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682225000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682225000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T05:19:21Z","timestamp":1772342361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682225000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":315,"alternative-id":["S0042682225000066"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2025.110394","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2025.110394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110394"}}